Results 111 to 120 of about 1,129 (187)

Use of azilsartan medoxomil in the primary-care setting in Germany: A real-world evidence study
. [PDF]

Int J Clin Pharmacol Ther, 2019
Ehlken B, Shlaen M, Lopez Fuensalida de Torres MDP, Hisada M, Bennett D.   +4 more
europepmc   +1 more source

Azilsartan medoxomil for stage 2 systolic hypertension [PDF]

Nature Reviews Nephrology, 2012
openaire   +1 more source

Statins, but not PCSK9 inhibitors, reduce the adipokine chemerin in familial hypercholesterolemia:Focus on lipoprotein subfractions [PDF]

, 2022
Jan Danser, A. H., Lu, Xifeng, Mulder, Monique T., Tan, Lunbo, Van Lennep, Jeanine Roeters, Van Vark Van Der Zee, Leonie, Verdonk, Koen, Wang, Na   +7 more
core   +1 more source

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum. [PDF]

Medicine (Baltimore), 2020
europepmc   +1 more source

Renal denervation in hypertensive patients not on blood pressure lowering drugs [PDF]

, 2016
Beeftink, M.M.A. (Martine M. A.), Blankestijn, P.J. (Peter), Bots, M.L. (Michiel), Böhm, B., Daemen, J. (Joost), De Jager, R.L. (Rosa L.), Dörr, O. (Oliver), Ewen, S. (Sebastian), Hering, D. (Dagmara), Lobo, M.D. (Melvin D.), Mahfoud, F. (Felix), Nef, H.M. (Holger), Ott, C. (Christian), Sanders, M.F., Saxena, M. (Manish), Schlaich, M.P. (Markus P.), Schmieder, R.E. (Roland), Spiering, W. (Wilko), Tonino, P. (Pim), Verloop, W.L. (Willemien L.), Vink, E.E. (Eva), Vonken, E.J.P.A., Voskuil, M. (Michiel), Worthley, S.G. (Stephen G.)   +23 more
core   +2 more sources

Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment. [PDF]

J Clin Pharmacol, 2018
Dudkowski C, Karim A, Zhao Z, Alonso AB, Garg D, Preston RA.   +5 more
europepmc   +1 more source

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. [PDF]

J Hypertens, 2018
Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.   +7 more
europepmc   +1 more source

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy. [PDF]

Core Evid, 2016
Angeloni E.
europepmc   +1 more source

Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed-Dose Combination in Healthy Adults. [PDF]

Clin Pharmacol Drug Dev, 2016
Dudkowski C, Karim A, Munsaka M.
europepmc   +1 more source

Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects. [PDF]

Clin Pharmacokinet, 2016
Harrell RE, Karim A, Zhang W, Dudkowski C.   +3 more
europepmc   +1 more source